UNC’s Baric Lab Key Contributor to Now Approved Remdesivir (Veklury®): Top Experts in Coronaviruses

UNC’s Baric Lab Key Contributor to Now Approved Remdesivir (Veklury®) Top Experts in Coronaviruses

Remdesivir has become a blockbuster drug in short time thanks in part to a pandemic-driven ACTIV-1 clinical trial and subsequent U.S. Food and Drug Administration (FDA) emergency use authorization (EUA) in May followed by permanent approval on October 22. Any successful drug development endeavor most often involves an intense collaboration between scientists and in this case the University of North Carolina Baric Lab deserves strong mention. Why? Because Remdesivir was developed via an academic-corporate partnership between Gilead Sciences and the Baric Lab at UNC's Chapel Hill’s Gillings School of Global Public Health. After all, Gilead needed the brain power associated with Ralph Baric and team. The William R. Kenan Jr. Distinguished Professor of Epidemiology has investigated coronaviruses for three decades and has actually pioneered rapid-response investigations of this class of pathogen. That’s how therapeutics come about and how this $1+ billion blockbuster, involved undoubtedly with many thankful patients, was made possible due in part to the work of Baric and team.

Recently, Elena Tsai writing for the the Daily Tar Heel reminded all the importance of this particular acad...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee